At the news
? NEUTRALIMPACT 5/10 8-K filed Aug 13, 2026 at 08:31 ET
Fate Therapeutics reported Q2 2026 results with a net loss of $0.25 per share, slightly beating the consensus estimate of -$0.26. The pre-revenue biotech's key catalysts are clinical milestones: first patient dosed in the potentially registrational RECLAIM-LN trial for FT819 in lupus nephritis, and FDA clearance of the FT839 IND for a Phase 1/2 autoimmune basket trial. Cash burn of $21M in the quarter leaves a runway into 2028, but with no revenue growth or path to profitability, the stock's direction hinges entirely on clinical execution and regulatory updates rather than financial performance.
- First patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 in lupus nephritis; patient treated as outpatient with same-day discharge.
- FDA cleared IND for FT839, a next-generation dual CD19/CD38 CAR T-cell product candidate, advancing into a Phase 1/2 basket trial in autoimmune disease.
- Cash, cash equivalents, and investments were $153.8M as of June 30, 2026, a quarterly decrease of $21M; cash runway expected into 2028.
- Net loss was $30.2M ($0.25 per share) for Q2 2026, compared to $34.1M ($0.29 per share) in Q2 2025.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access